Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

FEMARA 2,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/FEMARA 2,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

FEMARA 2,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA

Novartis Hellas S.A.C.I.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Dec 9, 2021
Approval ID: 3b963de846d5c7fa
Company: Novartis Hellas S.A.C.I.
Type: Standard

Approval Details

Approval Id: 3b963de846d5c7fa
Drug Cima Aemps Name: FEMARA 2,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 303848-10-2001IP
Holder Company Name: Novartis Hellas S.A.C.I.
Marketing Company Name: Elam Pharma Labs S.L.
Authorization Date: 2021-12-09
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 2.5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Novartis Hellas S.A.C.I.

Active Ingredients

LETROZOL

2,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Dec 9, 2021

Approval ID

3b963de846d5c7fa

Type

Standard

Back to CIMA-AEMPS Approvals